江汉大学学报(自然科学版) ›› 2020, Vol. 48 ›› Issue (4): 19-23.doi: 10.16389/j.cnki.cn42-1737/n.2020.04.003

• 医学 • 上一篇    下一篇

非布司他治疗痛风合并慢性肾功能不全的老年患者疗效观察

刘莉娟1,林梅*2   

  1. 1. 江汉大学 医学院,湖北 武汉 430056;2. 武汉市第四医院 内分泌科,湖北 武汉 430033
  • 发布日期:2020-08-06
  • 通讯作者: 林梅
  • 作者简介:刘莉娟(1993— ),女,硕士生,研究方向:痛风及其并发症的诊治。

Evaluation of Clinical Efficacy of Febuxostat in Treatment of Elderly Gout Patients with Chronic Renal Insufficiency

LIU Lijuan1,LIN Mei*2   

  1. 1. School of Medicine,Jianghan University,Wuhan 430056,Hubei,China;2. Department of Endocrine,Wuhan Forth Hospital,Wuhan 430033,Hubei,China
  • Published:2020-08-06
  • Contact: LIN Mei

摘要: 目 的 观察非布司他治疗痛风合并慢性肾功能不全老年患者的临床效果以及对肾功能的影响。方 法 回顾性分析武汉市第四医院2014 年1 月至2018 年12 月非布司他治疗的89 例老年痛风合并慢性肾功能不全患者。比较非布司他治疗前后血尿酸(UA)、尿素氮(BUN)、血肌酐(Scr)、肾小球滤过率(eGFR)的变化。结 果 ① 治疗后,老年痛风合并慢性肾功能不全患者的UA 和Scr 明显降低,差异有统计学意义,eGFR 有明显升高,差异有统计学意义。BUN 在治疗前后无明显改变。② 与治疗前相比,各组UA 在非布司他治疗后均有明显降低,差异有统计学意义,eGFR 在CKD 2 ~ 3 期患者中有明显升高,差异有统计学意义,而在CKD 4 期患者中无明显改变,差异无统计学意义。结 论 非布司他在治疗合并慢性肾功能不全的老年痛风患者时,其降尿酸水平的疗效较好,且非布司他有较好改善慢性肾功能不全2 ~ 3 期患者肾功能的作用。但对于已达到慢性肾功能不全4 期的老年痛风患者,非布司他对其肾功能的影响不明显,可能与研究中样本量较少有关。非布司他在中国人群中心血管安全性/心血管风险仍需要更多临床数据和更长时间的临床观察。

关键词: 非布司他, 痛风, 慢性肾功能不全, 老年患者

Abstract: Objective To evaluate the clinical effect and the influence on renal function of the elderly gout patients with chronic renal insufficiency treated by febuxostat. Methods A retrospective analysis of 89 elderly gout patients with chronic renal insufficiency from January 2014 to December 2018 was made. The changes of serum uric acid (UA),urea nitrogen(BUN),serum creatinine(Scr),and estimated glomerular filtration rate(eGFR) before and after treatment with febuxostat were compared. Results ① After treatment,the UA and Scr of elderly gout patients with chronic renal insufficiency were significantly reduced,with statistical significance,and eGFR was significantly increased,with statistical significance. There was no significant change in BUN before and after treatment. ② Compared with before treatment, UA in each group was significantly reduced after febuxostat treatment,the difference was statistically significant,eGFR was significantly increased in patients with CKD stage 2-3,the difference was statistically significant,and there was no significant change in patients with CKD stage 4,and the difference was not statistically significant. Conclusion In the treatment of elderly gout patients with chronic renal insufficiency,febuxostat is effective in lowering uric acid levels,and it has a better effect on improving renal function in patients with CKD stage 2-3. However,for elderly gout patients who have reached CKD stage 4,the effects of febuxostat are not obvious on renal function,which may be related to the small sample size in the study. More clinical data and longer clinical observation are needed for the cardiovascular safety/risk of febuxostat in China.

Key words: febuxostat, gout, chronic renal insufficiency, elderly patients

中图分类号: